Community Practice Connections™: 22nd Annual International Congress on the Future of Breast Cancer®
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
22nd Annual School of Breast Oncology
November 7-9, 2024
Register Now!
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Therapy Changes for Metastases and Toxicity Discussed in Breast Cancer
September 5th 2024During a Case-Based Roundtable® event, Ian Krop, MD, PhD, and event participants discussed how different types of metastases and treatment toxicity would affect therapy given to patients with triple-positive breast cancer in the second article of a 2-part series.
Tisa-cel Emerges as Earlier Option in Pediatric Acute Lymphoblastic Leukemia
The use of CAR T-cell therapy tisagenlecleucel has decreased the need for HSCT in pediatric and young adult patients with relapsed/refractory B-ALL, according to data from a noninterventional study.
Immunotherapy Opens a “New Era” in Treating T-Cell Malignancies
September 5th 2024Harnessing the power of the immune system has emerged as a key approach in addressing T-cell malignancies, with efforts to leverage the immune system leading to significant improvements beyond the traditional scope of surgery, radiation therapy, and chemotherapy.
FDA Oks FoundationOne CDx and Liquid CDx for Use With Olaparib/Abiraterone in Prostate Cancer
September 4th 2024The FDA has approved FoundationOne CDx and FoundationOne Liquid CDx as companion diagnostics to be used with olaparib, abiraterone, and prednisone or prednisolone BRCA-mutated metastatic castration-resistant prostate cancer.